摘要
“路线图”的概念根据以替比夫定为代表的核苷类药物治疗过程中HBVDNA下降的幅度与出现耐药性病毒突变明显相关的现象提出的。其核心内容是治疗后12周～24周的病毒学效应，对于预测和评估疗效具有重要意义。本文通过对“路线图”的概念、替比夫定“路线图”的临床试验依据及意义的介绍，阐明替比夫定治疗后12～24周的病毒学效应，对于预测和评估疗效具有重要意义；“路线图”对慢性乙型肝炎患者应用替比夫定治疗过程中调整治疗策略的指导意义，以规范临床治疗行为，规避耐药发生。
The name of ＂roadmap＂ is based on the relevance between the decreased amplitude of HBVDNA level and the appearance of HBV resistance during nucleos（t）ide analog anti--HBV treatment. It indicated that the virologic response at week 12 - 24 is predictive to identify the outcome. We will introduce the concept of ＂roadmap＂, the clinical basis of telbivudine treatment and significance of ＂roadmap＂ in this article, proving that the virologic response at week 12--24 is related to the outcome. And we will explain how to use the roadmap concept to optimize the management of patients with chronic hepatitis B and achieve the high potency and the lowest rate of HBV resistance.
出处
《医学与哲学（B）》
2009年第5期9-10,共2页
Medicine & Philosophy(B)
